Health committee  I can't speak to that. I think that's a clinical question.

Health committee  I don't want to say which one is doing it the best and which one is doing it the worst. I think what would work for Canada is looking at our needs and our context, considering the fact that we do have private insurance already. I think the U.K. has an interesting model where th

Health committee  I'm speaking as an individual. I studied part time in the U.K. I think it's quite wonderful that you access all medications without major service charges to individuals. There is an option to top-up with private insurance through employers.

Health committee  I think there needs to be a balance in Canada. Given that we've had this system in place for so long, there needs to be consultation to see what would work best going forward.

Health committee  Not that I'm aware of, no.

Health committee  I don't know that figure but there have been studies in Canada and elsewhere in the world, showing that issues with cost quite often lead to non-adherence, which then increases the risk for patients presenting with heart attacks in emergency departments. We are seeing that, ove

Health committee  I think it needs to be a phased approach. We're not going to solve this in a short time frame. Creating a vision with defining principles that we're striving to work towards is important. The consultation piece is very important too, so that's getting the patient voice and learni

Health committee  Thank you. Mr. Chair, committee members, on behalf of the Heart and Stroke Foundation, I'd like to thank you for the opportunity to appear before you and to share our perspectives on the development of a national pharmacare program in Canada. My name is Lesley James, and I'm the